Have you heard of MASH ((Metabolic Associated SteatoHepatitis)? Previously known as NASH (Non-Alcoholic SteatoHepatitis).
MASH, closely linked to obesity and type 2 diabetes epidemic, is a silent disease that has become a major cause of severe liver conditions like cirrhosis and hepatocellular carcinoma.
What are the solutions?
Despite preventive and therapeutic efforts, no fully specific and effective treatment is yet available for MASH:
- Pioglitazone is no longer marketed in France…
- GLP1 agonists and bariatric surgery (weight loss) habe shown some benefits, but…
- Resmetirom targets specific adults with a particular type of fibrosis…
Prof. Bernard BAUDUCEAU, former Head of the Endocrinology Department at BEGIN Hospital and Treasurer of the FFRD from 2013 to 2021, discusses a new promising avenue: survodutide, a dual agonist of glucagon and GLP-1 receptors… The highly encourging results from this trial would require phase 3 studies to confirm its therapeutic potential.
Article from Diabetes Experts Review in Diabétologie Pratique.